Therapies

Ferumoxides injectable solution

Feridex I.V.

This post is under:

Oncofocus Test Kit
includes suggestions for Ferumoxides injectable solution

Oncofocus is the world’s most comprehensive precision oncology test that precisely identifies the right drug for your cancer thereby increasing your chances of successful treatment.

Discover Oncofocus Today Do you want to order now? Request a test.

SUMMARY

Company: Advanced Magnetics
Approval Status:  FDA Approved February 1996
Specific Treatments: Liver cancer
Drug: Ferumoxides

 

GENERAL INFORMATION

Feridex I.V. (generic name ferumoxides injectable solution) has been approved as a contrast agent for magnetic resonance imaging (MRI) of liver lesions. Feridex I.V. is the first organ-specific MRI contrast agent to file with the FDA. Through the liver’s natural function, the agent is taken up by macrophages found only in healthy liver cells but not in most tumors.

 

ADDITIONAL INFORMATION

Feridex I.V. is marketed in the United States by Berlex Laboratories. If you have questions regarding Feridex I.V. please contact Berlex Laboratories, Inc. – Department of Epidemiology and Medical Affairs at (800) 888-2407.For product information call (800) 237-5391.

Feridex I.V. is marketed in western Europe by Guerbet S.A. under the tradename Endorem.

Feridex I.V. is marketed in Japan under the tradename Feridex by Eiken Chemical Co., Ltd, in association with Tanabe Seiyaku Ltd.

Feridex I.V. is marketed in Argentina by Temis-Lostaló, in South Korea byTaeJoon Pharmaceuticals, in Israel by Discotrade and in China by Pharmagenesis, Inc.

 

Source: centerwatch